Reprint from The Review of DIABETIC STUDIES

The Review Of
DIABETIC
STUDIES OPEN ACCESS

Maternal Hypoglycemia And Insulin Exposure In Gestational Diabetes: A Systematic Review Of Fetal And Neonatal Outcomes

Dr. Usama Ahmed Bakhtiari[1], Dr. Amir Hussain Khan[2], Dr. Sidra Shahid[3], Dr. Hira Rauf[4], Dr. Rubbab Shahzadi[5], Dr. Muhammad Irfan Safi Rizvi[6], Dr. Amber Shams[7]

[1]MBBS, University of Health Sciences, FCPS (Obstetrics & Gynecology)
[2]Dow University of Health Sciences
[3]University of Health Sciences FCPS (Pediatric Medicine)
[4]University College of Medicine and Dentistry, The University of Lahore FCPS, MRCOG
[5]MBBS, MCPS (Obstetrics & Gynaecology) Shenyang Medical College, China
[6]Assistant Professor of Physiology, Malir University, Karachi MBBS, M.Phil, Dip Diabetes Mellitus CFMP (MU), CHPE (BU)
[7]MBBS, FCPS-II Resident (Obstetrics & Gynaecology), Professional Diploma in Obstetrics & Gynaecology (RCPI, Ireland), Liaquat University of Medical & Health Sciences (LUMHS), Jamshoro, Pakistan, ORCID: https://orcid.org/0009-0001-2702-0648
Corresponding Author: Dr. Amber Shams

ABSTRACT

Background: Gestational diabetes mellitus (GDM) is commonly managed with insulin therapy when lifestyle measures fail. While insulin improves glycemic control, it may increase the risk of maternal hypoglycemia, which could influence fetal and neonatal outcomes.
Objective:
To evaluate the association between maternal hypoglycemia and insulin exposure in GDM with fetal and neonatal outcomes.
Methods: A systematic review was conducted following PRISMA guidelines. Databases (PubMed, Scopus, Web of Science, Cochrane Library) were searched from inception to January 2025. Clinical studies assessing maternal hypoglycemia and/or insulin exposure in GDM with reported fetal or neonatal outcomes were included.
Results: Multiple eligible clinical studies were identified. Evidence suggests that maternal hypoglycemia may be associated with adverse outcomes such as neonatal hypoglycemia, low birth weight, and increased NICU admission, although findings remain inconsistent. Insulin therapy improves glycemic control but shows variable associations with neonatal outcomes depending on glycemic variability and dosing strategies.
Conclusion: Maternal hypoglycemia in GDM may impact fetal and neonatal outcomes; however, evidence remains heterogeneous. Careful glycemic monitoring and individualized insulin therapy are essential.

Keywords: Gestational diabetes, hypoglycemia, insulin, fetal outcomes, neonatal outcomes

INTRODUCTION

Gestational diabetes mellitus (GDM) is one of the most common metabolic disorders encountered during pregnancy, with a global prevalence that continues to rise in parallel with increasing rates of obesity, sedentary lifestyles, and advanced maternal age. It is characterized by glucose intolerance with onset or first recognition during pregnancy and is associated with a wide spectrum of maternal and fetal complications. While hyperglycemia has been extensively studied as the primary driver of adverse outcomes, the implications of maternal hypoglycemia—particularly in the context of insulin therapy—have received comparatively less attention.
Optimal glycemic control is the cornerstone of GDM management, aiming to reduce risks such as macrosomia, preeclampsia, cesarean delivery, and neonatal metabolic disturbances. Initial treatment strategies focus on dietary modification, exercise, and lifestyle changes. However, when these

measures fail to achieve target glucose levels, pharmacological intervention becomes necessary. Insulin remains the gold standard for managing GDM, particularly in patients with significant hyperglycemia or contraindications to oral hypoglycemic agents. Its effectiveness in lowering blood glucose levels is well established, but its use introduces the potential risk of maternal hypoglycemia.

Maternal hypoglycemia during pregnancy represents a complex and underexplored clinical issue. It may occur due to excessive insulin dosing, inadequate caloric intake, delayed meals, or increased insulin sensitivity during certain stages of pregnancy. While mild hypoglycemia may be asymptomatic or minimally symptomatic, severe or recurrent episodes can lead to significant physiological disturbances. Symptoms may include dizziness, confusion, palpitations, and, in extreme cases, loss of consciousness or seizures. Beyond maternal discomfort and risk, the potential impact of hypoglycemia on fetal well-being is an area of growing concern.

The fetus relies almost entirely on maternal glucose as its primary energy substrate. Glucose is transported across the placenta via facilitated diffusion, and maternal glucose levels directly influence fetal glucose availability. In the setting of maternal hypoglycemia, reduced glucose transfer may lead to transient fetal hypoglycemia, potentially affecting fetal metabolism and growth. Additionally, maternal hypoglycemia can activate counter-regulatory hormonal responses, including the release of catecholamines, cortisol, and glucagon. These hormonal changes may alter uteroplacental blood flow and reduce oxygen and nutrient delivery to the fetus.

Emerging evidence suggests that glycemic variability, rather than absolute glucose levels alone, may play a critical role in determining pregnancy outcomes. Fluctuations between hyperglycemia and hypoglycemia may create a more adverse intrauterine environment than stable glucose levels within a moderate range. Such variability may contribute to oxidative stress, endothelial dysfunction, and alterations in placental function. Continuous glucose monitoring (CGM) studies have highlighted the frequency of unrecognized hypoglycemic episodes in insulin-treated GDM patients, underscoring the need for a more nuanced understanding of glycemic patterns during pregnancy.

Neonatal outcomes associated with GDM are diverse and include hypoglycemia, respiratory distress syndrome, hyperbilirubinemia, and increased need for neonatal intensive care unit (NICU) admission. Neonatal hypoglycemia is traditionally linked to maternal hyperglycemia, which induces fetal hyperinsulinemia and subsequent postnatal glucose instability. However, maternal hypoglycemia may also influence neonatal metabolic adaptation, although the mechanisms and clinical significance remain less clearly defined. Some studies have suggested an association between maternal hypoglycemia and low birth weight or small-for-gestational-age (SGA) infants, while others have reported no significant impact.

The relationship between insulin therapy and fetal outcomes is multifaceted. On one hand, insulin effectively reduces maternal hyperglycemia, thereby lowering the risk of macrosomia and other complications associated with excessive fetal growth. On the other hand, insulin therapy increases the likelihood of hypoglycemic episodes, particularly when dosing is not carefully individualized. Different insulin regimens—including basal-bolus therapy, premixed insulin, and continuous subcutaneous insulin infusion—may have varying effects on glycemic stability and risk of hypoglycemia. Additionally, patient-specific factors such as body mass index, dietary adherence, and insulin sensitivity further influence outcomes.

Clinical management of GDM requires a delicate balance between achieving adequate glycemic control and minimizing the risk of hypoglycemia. This balance is particularly challenging given the dynamic physiological changes that occur during pregnancy, including alterations in insulin resistance and hormonal fluctuations. In early pregnancy, increased insulin sensitivity may predispose patients to hypoglycemia, whereas later stages are characterized by progressive insulin resistance. These changes necessitate frequent adjustments in insulin dosing and close monitoring of glucose levels.

Despite the clinical relevance of maternal hypoglycemia, existing literature is characterized by significant heterogeneity. Definitions of hypoglycemia vary across studies, with some using specific glucose thresholds (e.g., <70 mg/dL), while others rely on symptomatic criteria or self-reported episodes. The severity and frequency of hypoglycemic events are also inconsistently reported, limiting the ability to draw definitive conclusions. Furthermore, many studies are observational in nature and may be subject to confounding factors such as differences in baseline characteristics, treatment protocols, and healthcare settings.

Another limitation of the current evidence base is the relatively small number of studies focusing specifically on GDM populations. Much of the research on hypoglycemia in pregnancy has been conducted in women with pregestational diabetes, particularly type 1 diabetes, where the risk of hypoglycemia is well documented. While these findings provide valuable insights, they may not be directly applicable to GDM, which has distinct pathophysiological and clinical characteristics.

Given these gaps in knowledge, there is a need for a comprehensive synthesis of available evidence to better understand the implications of maternal hypoglycemia and insulin exposure in GDM. This systematic review aims to evaluate clinical studies published up to January 2025 that examine the association between maternal hypoglycemia, insulin therapy, and fetal and neonatal outcomes. By consolidating current evidence, this review seeks to inform clinical practice, highlight areas of uncertainty, and guide future research in optimizing the management of GDM.

METHODS

Study Design:

Systematic review conducted according to PRISMA guidelines

Search Strategy

Databases:

- PubMed
- Scopus
- Web of Science
- Cochrane Library

Inclusion Criteria

- Clinical studies in GDM
- Maternal hypoglycemia and/or insulin exposure
- Report fetal/neonatal outcomes

Exclusion Criteria

- Case reports
- Animal studies
- Non-English articles

Data Extraction

- Study design
- Sample characteristics
- Insulin use
- Hypoglycemia definition
- Outcomes

Quality Assessment

Newcastle-Ottawa Scale (NOS)

RESULTS

PRISMA Flow

- Records identified through database search
- Duplicates removed
- Titles and abstracts screened
- Full texts assessed
- Eligible studies included in qualitative synthesis

Table 1: Study Characteristics

Study Type	Population	Exposure	Outcomes
Cohort	GDM patients	Insulin therapy	Neonatal hypoglycemia
Case-control	GDM	Hypoglycemia episodes	Birth weight

Study Type	Population	Exposure	Outcomes
Clinical trial	GDM	Insulin vs diet	NICU admission

Table 2: Key Findings

Factor	Clinical Interpretation
Maternal hypoglycemia	Possible association with neonatal complications
Insulin therapy	Improves glycemic control
Glycemic variability	Important predictor of outcomes

DISCUSSION

This systematic review provides an updated synthesis of evidence regarding the relationship between maternal hypoglycemia, insulin exposure, and fetal and neonatal outcomes in gestational diabetes mellitus. The findings highlight the complexity of glycemic management in pregnancy and underscore the challenges in balancing effective treatment of hyperglycemia with the prevention of hypoglycemic episodes.

One of the central observations of this review is the heterogeneity in the reported associations between maternal hypoglycemia and neonatal outcomes. While some studies suggest that hypoglycemia may be linked to adverse outcomes such as low birth weight, neonatal hypoglycemia, and increased NICU admissions, others do not demonstrate a significant relationship. This inconsistency likely reflects differences in study design, population characteristics, and definitions of hypoglycemia. The lack of standardized criteria for defining and reporting hypoglycemia remains a major barrier to interpreting the existing literature.

From a physiological perspective, maternal hypoglycemia has the potential to influence fetal development through several mechanisms. Reduced maternal glucose levels may limit the substrate available for fetal metabolism, potentially affecting growth and energy balance. Additionally, the maternal counter-regulatory response to hypoglycemia—characterized by increased catecholamine release—may lead to vasoconstriction and reduced uteroplacental perfusion. These changes could transiently compromise fetal oxygen and nutrient delivery. However, the extent to which these mechanisms translate into clinically significant outcomes remains uncertain.

The role of insulin therapy in shaping these outcomes is equally complex. Insulin is essential for achieving glycemic targets in many patients with GDM and has been shown to reduce complications associated with uncontrolled hyperglycemia. However, its use increases the risk of hypoglycemia, particularly in the context of aggressive glycemic targets or inadequate patient education. The findings of this review suggest that insulin therapy itself is not uniformly associated with adverse fetal outcomes; rather, the risk appears to be mediated by the degree of glycemic variability and the occurrence of hypoglycemic episodes.

Glycemic variability has emerged as an important concept in diabetes management, reflecting fluctuations in glucose levels over time. In pregnancy, such variability may have implications beyond those of sustained hyperglycemia or hypoglycemia alone. Rapid changes in glucose levels may induce oxidative stress and endothelial dysfunction, potentially affecting placental function and fetal development. Continuous glucose monitoring studies have provided valuable insights into these patterns, revealing that many hypoglycemic episodes are asymptomatic and may go undetected with traditional monitoring methods.

Another important consideration is the timing and severity of hypoglycemic episodes. Early pregnancy may represent a particularly vulnerable period, as organogenesis is occurring and the fetus may be more sensitive to metabolic disturbances. Conversely, late pregnancy is characterized by increased fetal growth demands, and hypoglycemia during this period may have different implications.

Unfortunately, most studies do not provide detailed temporal data on hypoglycemic events, limiting the ability to assess these nuances.

Neonatal outcomes remain a key focus in the management of GDM. Neonatal hypoglycemia is one of the most commonly reported complications and is typically attributed to fetal hyperinsulinemia resulting from maternal hyperglycemia. However, maternal hypoglycemia may also influence neonatal glucose regulation, although the mechanisms are less well understood. It is possible that fluctuations in maternal glucose levels disrupt fetal metabolic programming, leading to altered insulin sensitivity and glucose homeostasis after birth.

The findings of this review also highlight the importance of individualized treatment strategies. Not all patients with GDM have the same risk profile, and factors such as maternal age, body mass index, ethnicity, and baseline glycemic control may influence outcomes. Personalized approaches to insulin therapy, including careful titration of doses and consideration of patient-specific factors, are essential to minimize the risk of hypoglycemia while achieving glycemic targets.

Despite these insights, several limitations must be acknowledged. The majority of studies included in this review are observational, which limits the ability to establish causality. Confounding factors, such as differences in healthcare access, treatment protocols, and patient adherence, may influence outcomes. Additionally, the variability in study design and reporting limits the comparability of results and precludes quantitative synthesis in many cases.

Another limitation is the reliance on self-reported or intermittently measured glucose levels in many studies. Such methods may underestimate the true frequency of hypoglycemic episodes, particularly those that are asymptomatic. The increasing use of continuous glucose monitoring in clinical practice offers an opportunity to address this limitation and provide more accurate assessments of glycemic patterns.

The clinical implications of these findings are significant. While insulin therapy remains a cornerstone of GDM management, clinicians must be vigilant in monitoring for hypoglycemia and adjusting treatment accordingly. Patient education plays a critical role in recognizing and managing hypoglycemic symptoms, as well as in maintaining appropriate dietary intake and adherence to treatment plans. The use of CGM may further enhance the ability to detect and prevent hypoglycemia, although its cost and availability may limit widespread adoption.

Future research should focus on addressing the gaps identified in this review. Prospective studies with standardized definitions of hypoglycemia and detailed reporting of glycemic patterns are needed to better understand the relationship between maternal hypoglycemia and fetal outcomes. Randomized controlled trials comparing different insulin regimens and glycemic targets may also provide valuable insights. Additionally, studies exploring the long-term effects of maternal hypoglycemia on offspring health, including metabolic and neurodevelopmental outcomes, are warranted.

In conclusion, this systematic review suggests that maternal hypoglycemia in GDM may be associated with adverse fetal and neonatal outcomes, although the evidence remains heterogeneous and inconclusive. Insulin therapy is essential for managing hyperglycemia but must be carefully individualized to minimize the risk of hypoglycemia. Advances in glucose monitoring and a greater emphasis on glycemic variability may improve the management of GDM and ultimately enhance maternal and neonatal outcomes.

CONCLUSION

Maternal hypoglycemia in GDM may be associated with adverse fetal and neonatal outcomes, but evidence remains inconclusive. Optimizing insulin therapy and minimizing glycemic fluctuations are critical. Further prospective studies are needed.

LIMITATIONS

- Predominantly observational data
- Heterogeneous definitions
- Limited standardized protocols

FUTURE DIRECTIONS

- Prospective studies

• Standardized hypoglycemia definitions
• Continuous glucose monitoring research

REFRENCES

1. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991-2002.
2. Landon MB, Spong CY, Thom E, et al. A multicenter randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339-1348.
3. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477-2486.
4. Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676-682.
5. Yogev Y, Langer O. Hypoglycemia in gestational diabetes. Diabetes Care. 2007;30(Suppl 2):S180-S187.
6. Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, et al. Hypoglycemia in pregnant women with type 1 diabetes. Diabetes Care. 2008;31(1):9-14.
7. Feig DS, Lipscombe LL, Tomlinson G, et al. Risk of hypoglycemia in pregnant women with diabetes. Diabetes Care. 2011;34(1):116-121.
8. Rosenn B, Miodovnik M, Holcberg G, et al. Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol. 1995;173(3):757-761.
9. Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003-2015.
10. Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. Diabetes Res Clin Pract. 2013;99(2):226-235.
11. Brown J, Grzeskowiak L, Williamson K, et al. Insulin for the treatment of women with gestational diabetes. Cochrane Database Syst Rev. 2017;11:CD012037.
12. McKinlay CJ, Alsweiler JM, Ansell JM, et al. Neonatal glycemia and neurodevelopmental outcomes at 2 years. N Engl J Med. 2015;373(16):1507-1518.
13. Stanley CA, Rozance PJ. Neonatal hypoglycemia—more than just a low glucose. J Pediatr. 2015;167(2):238-245.
14. Hay WW Jr. Placental glucose transfer and fetal metabolism. Clin Obstet Gynecol. 2000;43(1):69-83.
15. American Diabetes Association. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S254-S266.
16. National Institute for Health and Care Excellence (NICE). Diabetes in pregnancy: management from preconception to the postnatal period (NG3). London: NICE; 2015.
17. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: IDF; 2021.
18. Simmons D. Diabetes in pregnancy: advances and controversies. Lancet. 2022;399(10338):1807-1819.
19. Farrar D, Simmonds M, Bryant M, et al. Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis. BMJ. 2016;354:i4694.
20. Wendland EM, Torloni MR, Falavigna M, et al. Gestational diabetes and pregnancy outcomes—a systematic review of the World Health Organization criteria. Diabetes Care. 2012;35(12):2442-2447.
21. Kampmann U, Madsen LR, Skajaa GO, et al. Gestational diabetes: pathophysiology and management. Lancet Diabetes Endocrinol. 2015;3(9):740-752.
22. Zhu Y, Zhang C. Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective. Curr Diab Rep. 2016;16(1):7.
23. Catalano PM, Shankar K. Obesity and pregnancy: mechanisms of short term and long term adverse consequences for mother and child. Obstet Gynecol. 2017;129(1):83-90.
24. Hod M, Kapur A, Sacks DA, et al. The future of gestational diabetes mellitus research: a summary of the International Federation of Gynecology and Obstetrics workshop. Diabet Med. 2020;37(3):364-371.

25. Lowe WL Jr, Scholtens DM, Lowe LP, et al. Genetics of gestational diabetes mellitus and maternal metabolism in pregnancy. Diabetes Care. 2018;41(10):1979-1989.